SHELL ASSET MANAGEMENT CO - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.

Quarter-by-quarter ownership
SHELL ASSET MANAGEMENT CO ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$122
-23.8%
3,425
-1.6%
0.01%
-16.7%
Q2 2023$160
+14.3%
3,479
-0.6%
0.01%0.0%
Q1 2023$140
-14.1%
3,499
-0.3%
0.01%
-14.3%
Q4 2022$163
-99.9%
3,511
-16.9%
0.01%0.0%
Q3 2022$175,000
-45.0%
4,224
-20.7%
0.01%
-22.2%
Q2 2022$318,000
-17.6%
5,329
+0.2%
0.01%0.0%
Q1 2022$386,000
-24.9%
5,321
-12.9%
0.01%
-18.2%
Q4 2021$514,000
-6.4%
6,108
+0.3%
0.01%
-8.3%
Q3 2021$549,000
-9.3%
6,087
-4.1%
0.01%0.0%
Q2 2021$605,000
-11.5%
6,347
+5.7%
0.01%
-14.3%
Q1 2021$684,000
+18.5%
6,007
+44.2%
0.01%
+16.7%
Q4 2020$577,000
+45.0%
4,167
-14.0%
0.01%
+33.3%
Q3 2020$398,000
+5.0%
4,8480.0%0.01%0.0%
Q2 2020$379,000
+73.1%
4,848
-1.7%
0.01%
+50.0%
Q1 2020$219,000
+2.3%
4,930
-1.5%
0.01%
+20.0%
Q4 2019$214,000
-2.7%
5,005
-2.6%
0.01%0.0%
Q3 2019$220,000
-33.1%
5,140
-0.8%
0.01%
-28.6%
Q2 2019$329,000
-10.6%
5,184
-2.2%
0.01%
-12.5%
Q1 2019$368,000
+60.0%
5,3010.0%0.01%
+33.3%
Q4 2018$230,000
-47.1%
5,301
-7.0%
0.01%
-33.3%
Q3 2018$435,0005,7010.01%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q1 2022
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 727,426$25,932,7374.72%
RTW INVESTMENTS, LP 5,405,089$192,691,4234.07%
First Light Asset Management, LLC 1,125,032$40,107,3913.81%
CHI Advisors LLC 215,000$7,664,7503.04%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 250,052$8,914,3543.00%
SPHERA FUNDS MANAGEMENT LTD. 259,135$9,238,1631.68%
Rock Springs Capital Management LP 1,476,441$52,635,1221.41%
SUVRETTA CAPITAL MANAGEMENT, LLC 679,459$24,222,7131.31%
Privium Fund Management B.V. 115,241$4,108,3411.22%
SECTOR GAMMA AS 115,166$4,105,6681.05%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders